Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce the appointment of James Williams to its Board as an independent nonexecutive director, effective 16 September 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce groundbreaking results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 30 June 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that Eurobio Scientific has been appointed to distribute its PromarkerD predictive test for diabetic kidney disease in France.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce it has engaged the medical device sales agency, Growth Medics B.V., to assist with the identification and selection of EU alliance partners for its PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to confirm the successful collaboration with Curtin University's Centre for Crop and Disease Management (CCDM), with researchers making an important breakthrough in understanding how dieback impacts plants.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2024.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to acquire approximately 600 patient plasma samples for its endometriosis study.
Proteomics International Laboratories Ltd (ASX:PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease.
Notice of Annual General Meeting/Proxy Form
Issue of Equity Incentives to Employees
Interim Financial Report and Appendix 4D
Issue of Equity Incentives to Employees
